Skip to main content
. 2017 Jun 23;12(6):e0179798. doi: 10.1371/journal.pone.0179798

Fig 8. KPC34 is active against an Ara-C resistant model of syngeneic murine ALL.

Fig 8

  • A) C57/Bl6 mice were injected with B6-ALL leukemia. Upon engraftment mice were treated with 100 mg/kg Ara-C until succumbing to disease. Mice were sacrificed and bilateral femur cells were harvested.
  • B) Viability assays of cells harvested from treated mice compared to parental cells. The indicated cells were treated for 72 hours with Ara-C and viability determined.
  • C) Kaplan-Meier curves for animals injected with Ara-C resistant B6-ALL cells. Upon engraftment mice were treated with saline p.o. or i.p., Ara-C at 7.1 mg/kg i.p. (Ara-C), Gemcitabine at 8.8 mg/kg i.p. (Gem), KPC34 at 20 mg/kg p.o. (KPC34).